Last reviewed · How we verify
Ethylenediamine dihydrochloride allergen patch
Ethylenediamine dihydrochloride serves as a contact allergen in patch testing to diagnose delayed-type hypersensitivity reactions and allergic contact dermatitis.
Ethylenediamine dihydrochloride serves as a contact allergen in patch testing to diagnose delayed-type hypersensitivity reactions and allergic contact dermatitis. Used for Diagnostic patch testing for ethylenediamine contact allergy and delayed-type hypersensitivity reactions.
At a glance
| Generic name | Ethylenediamine dihydrochloride allergen patch |
|---|---|
| Also known as | T.R.U.E. Test allergen ethylenediamine dihydrochloride |
| Sponsor | Allerderm |
| Drug class | Contact allergen diagnostic agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Allergy & Immunology |
| Phase | FDA-approved |
Mechanism of action
This compound is applied to the skin via a patch test to provoke a localized allergic reaction in sensitized individuals, allowing clinicians to identify contact allergen sensitivities. The reaction occurs through T-cell mediated immune response (Type IV hypersensitivity) when the allergen contacts skin in previously sensitized patients. It is used diagnostically rather than therapeutically.
Approved indications
- Diagnostic patch testing for ethylenediamine contact allergy and delayed-type hypersensitivity reactions
Common side effects
- Localized skin irritation or allergic reaction at patch site
- Erythema and induration at test site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: